membranes, and in the extracellular matrix. Because of their structural properties and omnipresence, the GAGs take part in vital biological processes such as cell-cell and cell-matrix interactions, modulation of growth factors, and cytokines activity and signaling. 3 We reviewed the novel pleiotropic effects of heparin and SLX in PD, the advantages and perspectives of their intraperitoneal administration, and possible mechanisms of these actions.
Extra-anticoagulant Effects of Heparin
Although inflammation precedes activation of other pathological processes, of particular importance is heparin's ability to influence almost all the steps of the inflammatory cascade. It blocks the L-selectins and P-selectins, other adhesive proteins, and inhibits inflammatory cell adhesion at the site of injury and further reduces their influx into the tissues. 2, 4 It is also capable of reducing activation of several inflammatory cells, which decreases cytokine (such as tumor necrosis factor-α, interleukins [IL]-1β, IL-6, IL-8) production, as well as translocation of nuclear factor-κB regulating their expression. 5, 6 In I ntraperitoneal heparin is commonly used in a setting of peritonitis in end-stage renal disease patients undergoing maintenance peritoneal dialysis (PD), mostly to diminish fibrin deposition and to prevent the occlusion of the peritoneal catheter and intra-abdominal adhesions. 1 Besides its anticoagulant actions, heparin exerts its diverse biological activities also by interactions with the numerous "heparin-binding proteins," which include growth factors, enzymes, chemokines, proteases and their inhibitors, as well as pathogen proteins. 2 Although the molecular aspect of those interactions is not completely understood, they apparently lead to changes in some proteins' properties and their abilities to modulate numerous biological effects, particularly in the peritoneal cavity. 2 Heparin-like commercial glycosaminoglycans (GAGs), for example, sulodexide (SLX), are also available. They resemble endogenous GAGs expressed by virtue of cells and present on their surface, in the basement Unfractionated heparin, low-molecular-weight heparins, and sulodexide belong to the family of glycosaminoglycans. Recent studies report on properties other than anticoagulant activities of these medications. They include modulation of cell growth and proliferation via actions on numerous growth factors affecting the immune system and matrix molecules production and degradation. Long-term peritoneal dialysis remarkably influences peritoneal cavity homeostasis by mechanisms mediated by growth factors. They initiate progression of pathological processes and further account for morphological and functional alterations of the peritoneal membrane. The best-recognized pathologies in peritoneal cavity under these conditions encompass inflammation, fibrosis, and vasculopathy, often leading to fatal encapsulating peritoneal sclerosis. Intraperitoneal heparin and its derivatives, by their pleiotropic actions, may influence these crucial processes and improve the peritoneal dialysis technique survival in a complex and so far understudied way. These issues, novel medical approaches, and their likely mechanisms have been reviewed.
Keywords: glycosaminoglycans; heparin; peritoneal dialysis; sulodexide addition to heparin's interference with the immune system, the drug also blunts complement activation. 2, 6 Heparin is a well-known inhibitor of various cells proliferation: fibroblasts, mesangial, epithelial, and vascular smooth muscle cells. 2 It also influences the extracellular matrix molecules production and degradation. Only recently unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) were shown to decrease collagen and fibronectin production and, in some cases, increase the GAGs production in animal models of hepatic, 7 lung, 8 and kidney fibrosis. 9 They were also shown to be beneficial in human fibrotic complications of chronic diseases such as viral hepatitis B. 10 The complex stimulatory and inhibitory effects of heparins on matrix metalloproteinases functions were also described. 6 The effects of heparin on fibrosis and angiogenesis are, at least in part, mediated by modulation of growth factors including pluripotent basic fibroblast growth factor (bFGF), transforming growth factor β1 (TGF-β1), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and others. 6, 11 
Peritoneal Dialysis, Heparin, and Sulodexide
Maintenance PD, although being an efficient and valuable mode of blood purification, 12 determines constant imbalance in the peritoneal cavity homeostasis and subsequently, morphological changes in the peritoneal membrane. Crucial factors predisposing to such alterations are unphysiological volumes of bioincompatible acidic dialysis fluid, 13 lactate buffer, 13, 14 high glucose concentration and glucosedegradation end products, resulting in increased production of advanced-glycation end-products (AGE), 13,15-17 recurrent episodes of peritonitis, 18 and antibiotics being administered directly into the peritoneal cavity. 19 With time, in the peritoneal membrane biopsy material, the loss of mesothelial cells can be observed, whereas the remaining cells show morphological abnormalities. 20 The thickness of submesothelial compact zone caused by increased fibrosis also increases with time on PD. 20, 21 Finally and inevitably, vasculopathy develops with blood vessel wall hyalinization, reduplication of subendothelial membrane, and neoangiogenesis. [20] [21] [22] As a consequence of morphological changes, functional alterations appear, loss of the osmotic gradient between hypertonic dialysis fluid and intravascular space results in increased transport of low-molecularweight solutes across the peritoneal membrane, and a decrease in ultrafiltration arises leading to failure of the dialysis technique. 22, 23 Intraperitoneal heparin is administered in animal models of PD and also in patients with acute peritonitis to inhibit fibrin generation resulting in catheter blocking and formation of peritoneal adhesions, and to prevent failure of the dialysis technique. Although heparin's influence on peritoneal structure and function in humans on PD is still not completely clear, increasing amount of data suggest that its extra-anticoagulant pleiotropic effects may also be beneficial. The influence of different GAGs on the peritoneal membrane structure and function was studied. Sulodexide-a mixture of heparan sulfate (80%) and dermatan sulfate (20%)-after intraperitoneal administration in long-term continuous ambulatory PD (CAPD) patients, was found to improve functional properties of peritoneal membrane by increasing the dialysate-to-plasma ratios of urea and creatinine and by decreasing peritoneal protein loss. 24 Further studies were performed to reveal whether its administration is also connected with preserving or improving the peritoneal morphology. Subcutaneous administration of SLX in a rat model of plasticizers-induced peritoneal sclerosis, except the functional improvement, also showed diminished histological alterations in the peritoneal membrane. In the GAG-treated rats, peritoneal changes involving inflammatory cells infiltration, fibrosis, and vascular pathology were present only in about 15% of peritoneal area as compared with the non treated rats. 25 Interestingly, oral treatment of CAPD patients with SLX ameliorated, in a dose dependent manner, peritoneal membrane function and decreased IL-1β, IL-6, and IL-8 peritoneal fluid concentrations, which was ascribed to the drug's remodeling activity in the peritoneum. 26 Blood coagulation parameters remained unchanged during the study and no difference in peritoneal glucose transport before and after SLX administration was observed. 26 Unchanged peritoneal glucose transport was also observed in a rat model of PD after intraperitoneal administration of UFH for 30 days compared with the group without heparin, 27 as well as in the study following a single injection or single dwell of LMWH. 28 It was parallel with increased peritoneal dialysate volume, thus suggesting that the healing properties of heparin could be responsible for the latter event. 27, 28 Because heparin was also found to be incorporated in the peritoneal membrane of rats (as shown by immunostaining), the interactions between this drug and proteins of peritoneal membrane seem to be a plausible explanation for the restoring properties of heparin. 29 Furthermore, the accumulation of heparin could have not only acute but also chronic modulatory effects on the structure and function of peritoneal membrane. On the one hand, in animal models of PD, it could interfere with study results, 29 but on the other hand, the potential benefits from heparin accumulation in patients on longterm PD, like for example, the reduction in dose and frequency of intraperitoneal heparin administration cannot be disregarded. The latter could be especially advantageous because heparin also was found to inhibit-in a dose-dependent manner-the proliferation of mesothelial cells in culture. 19 Although the conditions of growth and exposure to drugs of mesothelial cell culture and mesothelial cells in the peritoneal membrane under dialyses are very different. The impairment of the proliferation of these cells by heparin could not be excluded in vivo.
So far the largest human study of intraperitoneal heparin was the one conducted by Sjøland et al. 30 In a double-blinded placebo-controlled study, PD patients received LMWH tinzaparin, intraperitoneally once a day for 2 treatment periods of 3 months' duration, separated by a wash-out period of 1 month. The results showed that the concentration of glucose after 4 hours of the dwell compared with the concentration at the beginning of the dwell increased, as did the ultrafiltration in the LMWHtreated patients. In contrast to SLX treatment, 24 a significant decrease in the dialysate-to-plasma ratio was observed for creatinine and urea as compared with the placebo-treated group. Although SLX treatment seems to be more advantageous for the elimination of uremic toxins, the difference in the studies' design and drug compositions may be factors deciding on the various results in both the reports. 24, 30 However, dialysate-to-plasma ratio for albumin also increased in the tinzaparin-treated but not in the SLX-treated group. 24, 30 In the PD patients studied, markers of systemic and local inflammatory response were also monitored. 39 Although administered only into the peritoneal cavity, LMWH reduced plasma concentration of C-reactive protein by more than 25% compared with the placebo-treated group. Serum levels of IL-6 were reduced in the tinzaparin group at the end of treatment, and its concentration in dialysate was significantly decreased in the heparin versus placebo group. These results suggest that intraperitoneal LMWH heparin blunts not only local but also systemic inflammatory response in chronic PD patients. 31 It seems to be advantageous in view of cardiovascular complications, where persistent systemic inflammatory response remains the important cause of morbidity and death in dialysis patients. Importantly, the anti-factor Xa activity in plasma was not affected by intraperitoneal LMWH in this long-term study 31 ; this remains in line with a trial of a single intraperitoneal injection of LMWH enoxaparin. 32 Interestingly, none of the effects of tinzaparin administration in PD patients in the studies by Sjøland and coworkers 30, 31 was dependent on the initial division of patients to transporters subgroups status. Although the number of patients who completed the study was not impressive (n = 11), the described positive effects of intraperitoneal LMWH encourage further research.
Perspectives for Intraperitoneal Heparin and Sulodexide
At the basis of morphological alterations in peritoneal membrane on time on PD lay significant disturbances in various molecules' equilibrium. 33 Heparin and other GAGs, while exerting their activity by interactions with numerous proteins, may be not only preventive but also therapeutic remedies in these morbid conditions.
Conventional PD solutions contain high concentration of glucose degradation products (GDPs) as the effect of heat sterilization under acidic conditions. 34 GDPs lead to the formation of AGEs, which by interactions with their receptors (RAGEs) promote a wide variety of pathological pathways such as nuclear factor κB activation, TGF-β1, or VEGF overexpression. 33 In animal models of PD, switching from conventional to low GDP dialysis fluids, 13, 15 as well as inhibiting the AGE-RAGE interaction 16 resulted in no increase in inflammation, neoangiogenesis (unchanged VEGF expression), and fibrosis (no TGF-β overexpression) as compared with control animals. One of the latest studies showed that LMWH dalteparin was capable of directly and dosedependently blocking AGE-RAGE interaction, nuclear factor κB activity, and AGE-induced VEGF mRNA overexpression in cell cultures. 34 This study also revealed that LMWH administered subcutaneously or by an osmotic pump to a mouse model of diabetic nephropathy exerted preventive and therapeutic effects such as reduced urinary albumin/ creatinine ratio, glomerulosclerosis, suppressed expression of TGF-β1, and less mesangial expansion as compared with control diabetic group. 34 It seems plausible that the same effects of LMWH could be observed in peritoneal membrane; heparin may thus prevent or even treat fibrosis and vasculopathy in PD patients as well.
TGF-β1 is a well-studied cytokine responsible for fibrosis of different organs in pathological conditions, peritoneal membrane fibrosis 34 being one among them. In the peritoneum of long-term PD patients, TGF-β1 is responsible for epithelial to mesenchymal transition of mesothelial cells and further, for increased production of extracellular matrix proteins by myofibroblasts. 35 The cytokine is also known to enhance synthesis of matrix metalloproteinases inhibitors, block endothelial and epithelial cell growth, and induce their apoptosis. 34, 36 The expression of TGF-β1 in the peritoneal cavity by mesothelial cells and macrophages is strongly enhanced by high glucose concentration in dialysate solutions and at least partially mediated by AGE-RAGE interaction. 36 Taking into account that LMWH is capable of reducing TGF-β1 expression in animal model of diabetic nephropathy by inhibiting AGE-RAGE interactions as described above, and to completely inhibit TGF-β1 gene activation in glomerular mesangial cell culture stimulated with high glucose fluid, 37 implies that heparin is also an antifibrotic agent via TGF-β1 suppression.
Recently, HGF has emerged as an antifibrotic factor in PD. 38, 39 This cytokine is generally envisioned as an agent opposing TGF-β1 actions and possesses a wide variety of tissue-healing properties: mitogenic, motogenic, morphogenic, and anti-apoptotic. [40] [41] [42] [43] As shown in animal models of renal injury, endogenous as well as exogenous HGF markedly increased matrix metalloproteinase-9 expression and decreased the synthesis of tissue inhibitors of other metalloproteinases, 38 blocked epithelial to mesenchymal transition, 39 reduced fibronectin and type I collagen deposition, 42, 43 and repressed TGF-β1. 38, 42 Ameliorating effects of HGF on peritoneal fibrosis and TGF-β production were observed in human peritoneal mesothelial cell cultures 38 and mouse model of peritoneal damage. 39 Whereas HGF remains closely assembled with GAGs of cell surface and extracellular matrix, heparin is able to rapidly displace the growth factor to the circulation. Interestingly, both LMWH and UFH after administration in healthy human volunteers 44, 45 and hemodialysis patients 46, 47 caused an impressive increase in immunoreactive HGF blood concentration. The same striking effect was observed recently after intravenous injection of SLX into healthy volunteers. 48 Thus, it seems plausible that exogenous, and-hypothetically-intraperitoneal, GAGs have an enormous effect on omnipotent and tissue healing HGF upregulation.
In summary, a growing body of evidence on the extra-anticoagulant effects of heparins and SLX suggests that the GAG drugs, with their wide variety of pleiotropic and promising biological actions, may improve, prevent, or even treat peritoneal membrane damage in long-term PD patients, thus offering a new therapeutic approach.
